Self-aggregating 1.8 kDa polyethylenimines with dissolution switch at endosomal acidic pH are delivery carriers for plasmid DNA, mRNA, siRNA and exon-skipping oligonucleotides

Journal of Controlled Release

Volumn 246, Issue , 2017, Pages 60-70

  Chiper, Manuela ^a   Tounsi, Nassera ^a   Kole, Ryszard ^b   Kichler, Antoine ^a,c   Zuber, Guy ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GÉNÉTHON   (France)

Author keywords

Delivery system; Exon skipping; Gene delivery; mdx mice; mRNA delivery; Muscular dystrophy; Phosphorothioate RNA; Polyethylenimine (PEI); siRNA delivery; Transfection

Indexed keywords

AMIDES; AMINES; AROMATIC COMPOUNDS; CELL PROLIFERATION; CHEMICAL MODIFICATION; DNA; DRUG PRODUCTS; DRUG THERAPY; EFFICIENCY; GENE TRANSFER; GENES; MAMMALS; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; RNA;

DELIVERY SYSTEMS; EXON SKIPPING; GENE DELIVERY; MDX MICE; MRNA DELIVERY; MUSCULAR DYSTROPHY; PHOSPHOROTHIOATES; POLYETHYLENIMINES; SIRNA DELIVERY; TRANSFECTION;

OLIGONUCLEOTIDES;

COPOLYMER; DYSTROPHIN; MACROGOL; MESSENGER RNA; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; PLASMID DNA; POLYETHYLENEIMINE DERIVATIVE; SALICYLAMIDE DERIVATIVE; SMALL INTERFERING RNA; DNA; POLYETHYLENEIMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DUCHENNE MUSCULAR DYSTROPHY; ENDOSOME; EXON SKIPPING; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; EXON; GENE TRANSFER; GENETICS; HELA CELL LINE; PLASMID; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; DNA; EXONS; GENE TRANSFER TECHNIQUES; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MICE, INBRED MDX; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PLASMIDS; POLYETHYLENEIMINE; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 85006931080     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.12.005     Document Type: Article

References (62)

1. [1] Zuber, G., Dauty, E., Nothisen, M., Belguise, P., Behr, J.P., Towards synthetic viruses. Adv. Drug Deliv. Rev. 52 (2001), 245–253.
2. [2] De Smedt, S.C., Demeester, J., Hennink, W.E., Cationic polymer based gene delivery systems. Pharm. Res., 17, 2000, 113-26.
3. [3] Lachelt, U., Wagner, E., Nucleic acid therapeutics using polyplexes: a journey of 50 years (and beyond). Chem. Rev. 115 (2015), 11043–11078.
4. [4] Miyata, K., Nishiyama, N., Kataoka, K., Rational design of smart supramolecular assemblies for gene delivery: chemical challenges in the creation of artificial viruses. Chem. Soc. Rev. 41 (2012), 2562–2574.
5. [5] Sun, C., Tang, T., Uludag, H., Molecular dynamics simulations for complexation of DNA with 2 kDa PEI reveal profound effect of PEI architecture on complexation. J. Phys. Chem. B 116 (2012), 2405–2413.
6. [6] Merten, O.-W., Gaillet, B., Viral vectors for gene therapy and gene modification approaches. Biochem. Eng. J. 108 (2016), 98–115.
7. [7] Svyatchenko, V.A., Tarasova, M.V., Netesov, S.V., Chumakov, M., Oncolytic adenoviruses in anticancer therapy: current status and prospects. Mol. Biol. 46 (2012), 496–507.
8. [8] Mann, C.J., Honeyman, K., Cheng, A.J., Ly, T., Lloyd, F., Fletcher, S., et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 42–47.
9. [9] Nair, J.K., Willoughby, J.L., Chan, A., Charisse, K., Alam, M.R., Wang, Q., et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136 (2014), 16958–16961.
10. [10] Wong, S.Y., Sood, N., Putnam, D., Combinatorial evaluation of cations, pH-sensitive and hydrophobic moieties for polymeric vector design. Mol. Ther. 17 (2009), 480–490.
11. [11] Tavernier, G., Andries, O., Demeester, J., Sanders, N.N., De Smedt, S.C., Rejman, J., mRNA as gene therapeutic: how to control protein expression. J. Control. Release 150 (2011), 238–247.
12. [12] Troiber, C., Wagner, E., Nucleic acid carriers based on precise polymer conjugates. Bioconjug. Chem. 22 (2011), 1737–1752.
13. [13] Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., Anderson, D.G., Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15 (2014), 541–555.
14. [14] Glodde, M., Sirsi, S.R., Lutz, G.J., Physiochemical properties of low and high molecular weight poly(ethylene glycol)-grafted poly(ethylene imine) copolymers and their complexes with oligonucleotides. Biomacromolecules 7 (2006), 347–356.
15. [15] Alshamsan, A., Hamdy, S., Samuel, J., El-Kadi, A.O., Lavasanifar, A., Uludag, H., The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31 (2010), 1420–1428.
16. [16] Parhiz, H., Hashemi, M., Hatefi, A., Shier, W.T., Amel Farzad, S., Ramezani, M., Arginine-rich hydrophobic polyethylenimine: potent agent with simple components for nucleic acid delivery. Int. J. Biol. Macromol. 60 (2013), 18–27.
17. [17] Kim, C.W., Toita, R., Kang, J.H., Li, K., Lee, E.K., Zhao, G.X., et al. Stabilization of cancer-specific gene carrier via hydrophobic interaction for a clear-cut response to cancer signaling. J. Control. Release 170 (2013), 469–476.
18. [18] Guo, Z., Tian, H., Lin, L., Chen, J., He, C., Tang, Z., et al. Hydrophobic polyalanine modified hyperbranched polyethylenimine as high efficient pDNA and siRNA carrier. Macromol. Biosci. 14 (2014), 1406–1414.
19. [19] Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 7297–7301.
20. [20] Kunath, K., von Harpe, A., Fischer, D., Peterson, H., Bickel, U., Voigt, K., et al. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release 89 (2003), 113–125.
21. [21] Lecocq, M., Wattiaux-De Coninck, S., Laurent, N., Wattiaux, R., Jadot, M., Uptake and intracellular fate of polyethylenimine in vivo. Biochem. Biophys. Res. Commun. 278 (2000), 414–418.
22. [22] Merkel, O.M., Beyerle, A., Librizzi, D., Pfestroff, A., Behr, T.M., Sproat, B., et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol. Pharm. 6 (2009), 1246–1260.
23. [23] Beyerle, A., Irmler, M., Beckers, J., Kissel, T., Stoeger, T., Toxicity pathway focused gene expression profiling of PEI-based polymers for pulmonary applications. Mol. Pharm. 7 (2010), 727–737.
24. [24] Roques, C., Fattal, E., Fromes, Y., Comparison of toxicity and transfection efficiency of amphiphilic block copolymers and polycationic polymers in striated muscles. J. Gene Med. 11 (2009), 240–249.
25. [25] Malek, A., Merkel, O., Fink, L., Czubayko, F., Kissel, T., Aigner, A., In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol. Appl. Pharmacol. 236 (2009), 97–108.
26. [26] Fitzsimmons, R.E., Uludag, H., Specific effects of PEGylation on gene delivery efficacy of polyethylenimine: interplay between PEG substitution and N/P ratio. Acta Biomater. 8 (2012), 3941–3955.
27. [27] Liu, L., Zheng, M., Librizzi, D., Renette, T., Merkel, O.M., Kissel, T., Efficient and tumor targeted siRNA delivery by polyethylenimine-graft-polycaprolactone-block-poly(ethylene glycol)-folate (PEI-PCL-PEG-Fol). Mol. Pharm. 13 (2016), 134–143.
28. [28] Kircheis, R., Wightman, L., Schreiber, A., Robitza, B., Rossler, V., Kursa, M., et al. Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther. 8 (2001), 28–40.
29. [29] Ito, T., Yoshihara, C., Hamada, K., Koyama, Y., DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice. Biomaterials 31 (2010), 2912–2918.
30. [30] He, Y., Cheng, G., Xie, L., Nie, Y., He, B., Gu, Z., Polyethyleneimine/DNA polyplexes with reduction-sensitive hyaluronic acid derivatives shielding for targeted gene delivery. Biomaterials 34 (2013), 1235–1245.
31. [31] Fischer, D., Osburg, B., Petersen, H., Kissel, T., Bickel, U., Effect of poly(ethylene imine) molecular weight and pegylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metab. Dispos. 32 (2004), 983–992.
32. [32] Thomas, M., Ge, Q., JJ, L., Chen, J.Z., Klibanov, A.M., Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm. Res. 22 (2005), 373–380.
33. [33] Godbey, W.T., KK, W., Mikos, A.G., Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater. Res. 45 (1999), 268–275.
34. [34] Shim, M.S., Kwon, Y.J., Controlled cytoplasmic and nuclear localization of plasmid DNA and siRNA by differentially tailored polyethylenimine. J. Control. Release 133 (2009), 206–213.
35. [35] Teo, P.Y., Yang, C., Hedrick, J.L., Engler, A.C., Coady, D.J., Ghaem-Maghami, S., et al. Hydrophobic modification of low molecular weight polyethylenimine for improved gene transfection. Biomaterials 34 (2013), 7971–7979.
36. [36] Remant Bahadur, K.C., Uludag, H., A comparative evaluation of disulfide-linked and hydrophobically-modified PEI for plasmid delivery. J. Biomater. Sci. Polym. Ed. 22 (2011), 873–892.
37. [37] Frohlich, T., Edinger, D., Klager, R., Troiber, C., Salcher, E., Badgujar, N., et al. Structure-activity relationships of siRNA carriers based on sequence-defined oligo (ethane amino) amides. J. Control. Release 160 (2012), 532–541.
38. [38] Creusat, G., Zuber, G., Self-assembling polyethylenimine derivatives mediate efficient siRNA delivery in mammalian cells. Chembiochem 9 (2008), 2787–2789.
39. [39] Creusat, G., Rinaldi, A.S., Weiss, E., Elbaghdadi, R., Remy, J.S., Mulherkar, R., et al. Proton sponge trick for pH-sensitive disassembly of polyethylenimine-based siRNA delivery systems. Bioconjug. Chem. 21 (2010), 994–1002.
40. [40] Pinel, S., Aman, E., Erblang, F., Dietrich, J., Frisch, B., Sirman, J., et al. Quantitative measurement of delivery and gene silencing activities of siRNA polyplexes containing pyridylthiourea-grafted polyethylenimines. J. Control. Release 182 (2014), 1–12.
41. [41] Philippe, L., Alsaleh, G., Pichot, A., Ostermann, E., Zuber, G., Frisch, B., et al. MiR-20a regulates ASK1 expression and TLR4-dependent cytokine release in rheumatoid fibroblast-like synoviocytes. Ann. Rheum. Dis. 72 (2013), 1071–1079.
42. [42] Creusat, G., Thomann, J.S., Maglott, A., Pons, B., Dontenwill, M., Guerin, E., et al. Pyridylthiourea-grafted polyethylenimine offers an effective assistance to siRNA-mediated gene silencing in vitro and in vivo. J. Control. Release 157 (2012), 418–426.
43. [43] Judge, A.D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J. Clin. Invest. 119 (2009), 661–673.
44. [44] Kang, S.H., Cho, M.J., Kole, R., Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37 (1998), 6235–6239.
45. [45] Harding, P.L., Fall, A.M., Honeyman, K., Fletcher, S., Wilton, S.D., The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol. Ther. 15 (2007), 157–166.
46. [46] Chandrashekhar, C., Pons, B., Muller, C.D., Tounsi, N., Mulherkar, R., Zuber, G., Oligobenzylethylenimine enriches linear polyethylenimine with a pH-sensitive membrane-disruptive property and leads to enhanced gene delivery activity. Acta Biomater. 9 (2013), 4985–4993.
47. [47] Zuber, G., Dontenwill, M., Behr, J.P., Synthetic Viruslike particles for targeted gene delivery to alpha(v)beta(3) integrin-presenting endothelial cells. Mol. Pharm. 6 (2009), 1544–1552.
48. [48] von Harpe, A., Petersen, H., Li, Y., Kissel, T., Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release 69 (2000), 309–322.
49. [49] Sonawane, N.D., Szoka, F.C. Jr., Verkman, A.S., Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278 (2003), 44826–44831.
50. [50] Bettinger, T., Carlisle, R.C., Read, M.L., Ogris, M., Seymour, L.W., Peptide-mediated, R.N.A., Delivery: a novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res. 29 (2001), 3882–3891.
51. [51] Rejman, J., Tavernier, G., Bavarsad, N., Demeester, J., De Smedt, S.C., mRNA transfection of cervical carcinoma and mesenchymal stem cells mediated by cationic carriers. J. Control. Release 147 (2010), 385–391.
52. [52] Sazani, P., Kole, R., Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J. Clin. Invest. 112 (2003), 481–486.
53. [53] Kole, R., Krieg, A.M., Exon skipping therapy for Duchenne muscular dystrophy. Adv. Drug Deliv. Rev. 87 (2015), 104–107.
54. [54] Zaghloul, E.M., Viola, J.R., Zuber, G., Smith, C.I.E., Lundin, K.E., Formulation and delivery of splice-correction antisense oligonucleotides by amino acid modified polyethylenimine. Mol. Pharm. 7 (2010), 652–663.
55. [55] FDA issues complete response letter for KyndrisaTM for Duchenne muscular dystrophy amenable to exon 51 skipping. http://investors.bmrn.com/releasedetail.cfm?releaseid=9503092016.
56. [56] FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm2016.
57. [57] Wang, M., Wu, B., Lu, P., Tucker, J.D., Milazi, S., Shah, S.N., et al. Pluronic-PEI copolymers enhance exon-skipping of 2′-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice. Gene Ther. 21 (2014), 52–59.
58. [58] Bremmer-Bout, M., Aartsma-Rus, A., de Meijer, E.J., Kaman, W.E., Janson, A.A., Vossen, R.H., et al. Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol. Ther. 10 (2004), 232–240.
59. [59] QL, L., Liang, H.D., Partridge, T., Blomley, M.J., Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 10 (2003), 396–405.
60. [60] Williams, J.H., Sirsi, S.R., Latta, D.R., Lutz, G.J., Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers. Mol. Ther. 14 (2006), 88–96.
61. [61] Lozach, P.Y., Huotari, J., Helenius, A., Late-penetrating viruses. Curr. Opin. Virol. 1 (2011), 35–43.
62. [62] Lukacs, G.L., Haggie, P., Seksek, O., Lechardeur, D., Freedman, N., Verkman, A.S., Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275 (2000), 1625–1629.